Pre-antiretroviral treatment (ART) characteristics stratified by the modification made to the ART regimen among 294 children treated for TB and 232 comparison children not treated for TB at each site.

a<p>Denominators in each group are as shown.</p>b<p>superboosted LPV/r group significantly different from Shezi comparisons p<0.05.</p>c<p>double dose LPV/r group significantly different from Shezi comparisons p<0.05.</p>d<p>ritonavir group significantly different from Neverest comparisons p<0.05.</p

Flow diagram of study participants.

<p>Flow diagram of study participants.</p

Virologic, clinical and immunological outcomes at 6 and 12 months between children co-treated for TB stratified by the modifications made to their PI-based regimen and comparisons not co-treated for TB.

a<p>super-boosted LPV/r group significantly different from comparisons p<0.05,</p>b<p>double dose LPV/r group significantly different from comparisons p<0.05.</p>c<p>ritonavir group significantly different from Neverest comparisons.</p

Toxicity outcomes during 12 months after initiation of TB co-treatment by modification made to the PI-containing regimen.

a<p>Toxicity outcomes in children on superboosted LPV/r significantly different to children taking ritonavir only if ≥ grade 1 is selected as the cut-off.</p

Characteristics of children who initiated TB treatment by modification made to antiretroviral treatment (ART) regimen.

*<p>Percents add up to >100% because more than one type of TB or diagnostic intervention was possible in the same child.</p>**<p>Other diagnostic evaluations include lymph node biopsy (2), gastric washing (1).</p>***<p>Other medications include prednisone (3), ciprobay (3), ethambutol (3).</p